Bengaluru & Delhi: HORIBA a medical diagnostic company on Monday announced its partnership with SigTuple to accelerate the adoption of its AI100, a solution for AI-assisted digital pathology, across the Indian subcontinent.
SigTuple’s AI100 AI based cell classification is presented to a pathologist on a cloud platform, standardising the quality and increasing the efficiency of the pathologist multifold. Further, showcasing the microscopic view of the slide remotely, drives seamless transition from manual microscopy to digital microscopy and enables tele-pathology.
SigTuple’s AI100 currently automates the microscopic review of the two most common tests coming to the lab – peripheral blood smear and urine, with plans to add AI capabilities for more tests on the same platform.
“AI100 added to HORIBA’s existing portfolio, enables a complete automation solution to be offered to all labs. This partnership will go a long way in driving the adoption of AI powered digital cell morphology across the Indian subcontinent. This is also one of the first, if not the first, instance of a global medical device major getting into a distribution partnership with an Indian start-up,” said Dr Tathagato Rai Dastidar, Founder and CEO at SigTuple.
Commenting on the partnership, Dr Rajeev Gautam, Corporate Officer, HORIBA Ltd., Japan and President, HORIBA India Pvt.Ltd, said, “This strategic partnership will be built on the synergies of the complimentary nature of products that SigTuple would be offering to further strengthen the HORIBA product basket. We are glad to optimize on our market penetration and customer connect to make this partnership a success in India and global markets”.